<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01919411</url>
  </required_header>
  <id_info>
    <org_study_id>11-053H</org_study_id>
    <nct_id>NCT01919411</nct_id>
  </id_info>
  <brief_title>Prophylactic Antibiotics After Functional Endoscopic Sinus Surgery: a Randomized, Double-blind Placebo Controlled Trial</brief_title>
  <official_title>Prophylactic Antibiotics After Functional Endoscopic Sinus Surgery: a Randomized, Double-blind Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts Eye and Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Surgeons commonly prescribe post operative prophylactic antibiotics after sinus surgery.
      There is minimal data to support this. The investigators' study will aim to demonstrate that
      patients' quality of life and rate of post operative infection is the same whether they
      receive or do not receive antibiotics post operatively. The investigators hypothesis is that
      the disease specific quality of life of patients taking post-operative antibiotics is not
      inferior to the quality of life of patients who do not take post-operative antibiotics, and
      the rate of post-operative infections are the same. The investigators' specific aim is to
      compare validated symptom scores between post-operative populations who are given or are not
      given antibiotics. Rates of infections in the first 10 days after surgery will be recorded.
      The investigators will also compare endoscopic grades of sinus cavities during the
      post-operative follow up exams as an additional outcome measure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Functional endoscopic sinus surgery (FESS) is a commonly performed procedure in the United
      States to treat chronic rhinosinusitis. Common practice is to prescribe prophylactic
      antibiotics postoperatively. This is similar to the long tradition of prophylactic
      antibiotics after tonsillectomy. The American Academy of Otolaryngology - Head and Neck
      Surgery recently strongly recommended against prophylactic antibiotics after tonsillectomy.
      In this light, this study would demonstrate the lack of need for antibiotics after FESS.
      Currently one surgeon does not prescribe antibiotics except when evidence of active infection
      was found during surgery. The other surgeon in the study currently prescribes antibiotics.
      This study would prospectively compare the two groups in a randomized fashion. The
      investigators' plan to use the Sinonasal outcomes test - 22 (SNOT-22) as the investigators'
      primary outcomes measure, which is a validated quality of life instrument in sinusitis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">September 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sinonasal Outcome Test - 22</measure>
    <time_frame>One week post operatively</time_frame>
    <description>The sinonasal outcome test -22 (SNOT-22) is a validated instrument for measuring quality of life outcomes in chronic sinusitis.
Snot-22 scores can range from 0 to 110. Higher scores indicate more severe symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sinonasal Outcome Test - 22</measure>
    <time_frame>Six weeks post operatively</time_frame>
    <description>The sinonasal outcome test -22 (SNOT-22) is a validated instrument for measuring quality of life outcomes in chronic sinusitis.
Snot-22 scores can range from 0 to 110. Higher scores indicate more severe symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lund Kennedy Endoscopic Score</measure>
    <time_frame>One week postoperatively</time_frame>
    <description>The Lund Kennedy endoscopic score is a grading system for visually evaluating patient's sinus cavities before and after surgery. It has five measures to score (polyps, edema, discharge, scarring, and crusting).
Scores range from 0 to 20 with higher scores indicating greater sinus disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lund Kennedy Endoscopic Score</measure>
    <time_frame>Six weeks postoperatively</time_frame>
    <description>The Lund Kennedy endoscopic score is a grading system for visually evaluating patient's sinus cavities before and after surgery. It has five measures to score (polyps, edema, discharge, scarring, and crusting).
Scores range from 0 to 20 with higher scores indicating greater sinus disease.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Post Operative Infection</measure>
    <time_frame>One week postoperatively</time_frame>
    <description>The investigators will record the rate of post operative infections in the two groups.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Post Operative Infection</measure>
    <time_frame>Six weeks postoperatively</time_frame>
    <description>The investigators will record the rate of post operative infections in the two groups.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Sinusitis</condition>
  <arm_group>
    <arm_group_label>Amoxicillin-Potassium Clavulanate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of augmentin (amoxicillin-clavulanate) 500mg orally twice a day after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of placebo orally twice a day after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin-Potassium Clavulanate</intervention_name>
    <description>Patients in this arm will receive 500mg of Amoxicillin-Potassium Clavulanate Combination orally twice a day for 7 days after surgery.</description>
    <arm_group_label>Amoxicillin-Potassium Clavulanate</arm_group_label>
    <other_name>Augmentin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients in this arm will receive 7 days of placebo after surgery.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patients eligible for surgery would be patients with chronic rhinosinusitis (defined by
        the AAOHNS 2007 consensus statement by Rosenfeld et al) and have been determined by their
        surgeons to have persistent symptoms after maximal medical therapy. Maximal medical therapy
        is defined as a course of broad spectrum or culture-directed antibiotics used in
        conjunction with a nasal steroid.

        Exclusion Criteria:

          1. Penicillin, cephalosporin, amoxicillin/clavulanate allergy

          2. Cystic Fibrosis

          3. Immunodeficiency

          4. Presence of any foreign body (ie.absorbable and non-absorbable packing) after surgery

          5. Odontogenic causes of sinusitis

          6. Fungal ball

          7. Infected mucocele

          8. Complication of sinusitis (meningitis, orbital complication, cellulitis, brain
             abscess)

          9. Non endoscopic sinus surgery (Caldwell luc, external approaches, etc)

         10. Age &lt;18

         11. Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric H Holbrook, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MEEI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item Sinonasal Outcome Test. Clin Otolaryngol. 2009 Oct;34(5):447-54. doi: 10.1111/j.1749-4486.2009.01995.x.</citation>
    <PMID>19793277</PMID>
  </reference>
  <reference>
    <citation>Rosenfeld RM, Andes D, Bhattacharyya N, Cheung D, Eisenberg S, Ganiats TG, Gelzer A, Hamilos D, Haydon RC 3rd, Hudgins PA, Jones S, Krouse HJ, Lee LH, Mahoney MC, Marple BF, Mitchell CJ, Nathan R, Shiffman RN, Smith TL, Witsell DL. Clinical practice guideline: adult sinusitis. Otolaryngol Head Neck Surg. 2007 Sep;137(3 Suppl):S1-31.</citation>
    <PMID>17761281</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 1, 2013</study_first_submitted>
  <study_first_submitted_qc>August 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2013</study_first_posted>
  <results_first_submitted>January 28, 2020</results_first_submitted>
  <results_first_submitted_qc>January 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 10, 2020</results_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts Eye and Ear Infirmary</investigator_affiliation>
    <investigator_full_name>Eric Holbrook</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Chronic rhinosinusitis</keyword>
  <keyword>Sinus surgery</keyword>
  <keyword>Antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 6, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT01919411/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 28, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT01919411/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>134 participants signed consent, but only 89 were randomized. The remainder failed screening.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Amoxicillin-Potassium Clavulanate</title>
          <description>All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of augmentin (amoxicillin-clavulanate) 500mg orally twice a day after surgery.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of placebo orally twice a day after surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Amoxicillin-Potassium Clavulanate</title>
          <description>All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of augmentin (amoxicillin-clavulanate) 500mg orally twice a day after surgery.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of placebo orally twice a day after surgery.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="41"/>
                    <count group_id="B3" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="41"/>
                    <count group_id="B3" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.5" lower_limit="18.5" upper_limit="67.3"/>
                    <measurement group_id="B2" value="40.8" lower_limit="21.8" upper_limit="67.1"/>
                    <measurement group_id="B3" value="43.65" lower_limit="18.5" upper_limit="67.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="41"/>
                    <count group_id="B3" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="41"/>
                    <count group_id="B3" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lund Kennedy Endoscopic Score</title>
          <description>The Lund Kennedy endoscopic score is a grading system for visually evaluating patient's sinus cavities before and after surgery. It has five measures to score (polyps, edema, discharge, scaring, and crusting).
Scores range from 0 to 20 with higher scores indicating greater sinus disease.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="41"/>
                    <count group_id="B3" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.2" lower_limit="4" upper_limit="14"/>
                    <measurement group_id="B2" value="8.2" lower_limit="1" upper_limit="14"/>
                    <measurement group_id="B3" value="8.2" lower_limit="1" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SNOT-22 Scores</title>
          <description>The sinonasal outcome test -22 (SNOT-22) is a validated instrument for measuring quality of life outcomes in chronic sinusitis.
Snot-22 scores can range from 0 to 110. Higher scores indicate more severe symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="41"/>
                    <count group_id="B3" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.8" lower_limit="0" upper_limit="93"/>
                    <measurement group_id="B2" value="39.0" lower_limit="10" upper_limit="84"/>
                    <measurement group_id="B3" value="43.4" lower_limit="0" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sinonasal Outcome Test - 22</title>
        <description>The sinonasal outcome test -22 (SNOT-22) is a validated instrument for measuring quality of life outcomes in chronic sinusitis.
Snot-22 scores can range from 0 to 110. Higher scores indicate more severe symptoms.</description>
        <time_frame>One week post operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin-Potassium Clavulanate</title>
            <description>All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of augmentin (amoxicillin-clavulanate) 500mg orally twice a day after surgery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of placebo orally twice a day after surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Sinonasal Outcome Test - 22</title>
          <description>The sinonasal outcome test -22 (SNOT-22) is a validated instrument for measuring quality of life outcomes in chronic sinusitis.
Snot-22 scores can range from 0 to 110. Higher scores indicate more severe symptoms.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3" spread="21.7"/>
                    <measurement group_id="O2" value="31.0" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sinonasal Outcome Test - 22</title>
        <description>The sinonasal outcome test -22 (SNOT-22) is a validated instrument for measuring quality of life outcomes in chronic sinusitis.
Snot-22 scores can range from 0 to 110. Higher scores indicate more severe symptoms.</description>
        <time_frame>Six weeks post operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin-Potassium Clavulanate</title>
            <description>All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of augmentin (amoxicillin-clavulanate) 500mg orally twice a day after surgery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of placebo orally twice a day after surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Sinonasal Outcome Test - 22</title>
          <description>The sinonasal outcome test -22 (SNOT-22) is a validated instrument for measuring quality of life outcomes in chronic sinusitis.
Snot-22 scores can range from 0 to 110. Higher scores indicate more severe symptoms.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" spread="21.5"/>
                    <measurement group_id="O2" value="17.5" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lund Kennedy Endoscopic Score</title>
        <description>The Lund Kennedy endoscopic score is a grading system for visually evaluating patient's sinus cavities before and after surgery. It has five measures to score (polyps, edema, discharge, scarring, and crusting).
Scores range from 0 to 20 with higher scores indicating greater sinus disease.</description>
        <time_frame>One week postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin-Potassium Clavulanate</title>
            <description>All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of augmentin (amoxicillin-clavulanate) 500mg orally twice a day after surgery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of placebo orally twice a day after surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Lund Kennedy Endoscopic Score</title>
          <description>The Lund Kennedy endoscopic score is a grading system for visually evaluating patient's sinus cavities before and after surgery. It has five measures to score (polyps, edema, discharge, scarring, and crusting).
Scores range from 0 to 20 with higher scores indicating greater sinus disease.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="1.8"/>
                    <measurement group_id="O2" value="5.9" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lund Kennedy Endoscopic Score</title>
        <description>The Lund Kennedy endoscopic score is a grading system for visually evaluating patient's sinus cavities before and after surgery. It has five measures to score (polyps, edema, discharge, scarring, and crusting).
Scores range from 0 to 20 with higher scores indicating greater sinus disease.</description>
        <time_frame>Six weeks postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin-Potassium Clavulanate</title>
            <description>All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of augmentin (amoxicillin-clavulanate) 500mg orally twice a day after surgery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of placebo orally twice a day after surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Lund Kennedy Endoscopic Score</title>
          <description>The Lund Kennedy endoscopic score is a grading system for visually evaluating patient's sinus cavities before and after surgery. It has five measures to score (polyps, edema, discharge, scarring, and crusting).
Scores range from 0 to 20 with higher scores indicating greater sinus disease.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="2.6"/>
                    <measurement group_id="O2" value="4.5" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Post Operative Infection</title>
        <description>The investigators will record the rate of post operative infections in the two groups.</description>
        <time_frame>One week postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin-Potassium Clavulanate</title>
            <description>All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of augmentin (amoxicillin-clavulanate) 500mg orally twice a day after surgery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of placebo orally twice a day after surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Post Operative Infection</title>
          <description>The investigators will record the rate of post operative infections in the two groups.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Post Operative Infection</title>
        <description>The investigators will record the rate of post operative infections in the two groups.</description>
        <time_frame>Six weeks postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin-Potassium Clavulanate</title>
            <description>All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of augmentin (amoxicillin-clavulanate) 500mg orally twice a day after surgery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of placebo orally twice a day after surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Post Operative Infection</title>
          <description>The investigators will record the rate of post operative infections in the two groups.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Follow-ups at one week post-surgery and then 6 weeks post-surgery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Amoxicillin-Potassium Clavulanate</title>
          <description>All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of augmentin (amoxicillin-clavulanate) 500mg orally twice a day after surgery.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of placebo orally twice a day after surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Eric Holbrook</name_or_title>
      <organization>Massachusetts Eye &amp; Ear Infirmary</organization>
      <phone>617-573-3209</phone>
      <email>Eric_Holbrook@meei.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

